SCHEMBL6497815

SCHEMBL6497815

CC(Oc1ccccc1)C(=O)N1Cc2ccc(NC(=O)C3=C(c4ccc(Br)cc4)CCCC3)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 3/20 0.44
▸ HPGD P15428 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ L3MBTL3 Q96JM7 1/20 0.39
▸ DHODH Q02127 3/20 0.38
▸ NR4A2 P43354 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ TMPRSS2 O15393 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497655 0.71 MELK (0.50) DHODH
SCHEMBL10054188 0.69 HPGD (0.80) HPGDLMNATSHRCRHBPMAPK1
SCHEMBL6490462 0.67 NAMPT (0.45) NAMPTSMN1; SMN2TMPRSS2NPC1RAB9A
SCHEMBL6488027 0.64 ESR2 (0.50) NAMPTTMPRSS2NPC1RAB9A
SCHEMBL6644758 0.64 RAB9A (0.40) NAMPTHPGDLMNATSHRMAPK1
SCHEMBL17960424 0.63 ALOX15 (0.47) HPGDSMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL29237588 0.63 DPP8 (0.54) NAMPTSLC6A4HSD17B3DPP8DPP9
SCHEMBL29237591 0.63 DPP8 (0.54) NAMPTSLC6A4HSD17B3DPP8DPP9
SCHEMBL30967882 0.63 DPP8 (0.54) NAMPTSLC6A4HSD17B3DPP8DPP9
SCHEMBL3709766 0.63 NAMPT (1.00) NAMPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 NAMPT 2426/4885HPGD 2564/4885LMNA 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback